Inhibitor Therapeutics (INTI) Net Equity Issued and Repurchased (2014)
Inhibitor Therapeutics' (INTI) quarterly Net Equity Issued and Repurchased came in at $550000.0 in Q4 2014, little changed on a QoQ basis from $550000.0 in Q3 2014.
Inhibitor Therapeutics (INTI) Net Equity Issued and Repurchased (2014) Analysis & Trends
Inhibitor Therapeutics (INTI) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $550000.0 in Q4 2014.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $550000.0 in Q4 2014, while the trailing twelve-month figure through Sep 2016 was $550000.0 (changed N/A YoY) and the FY2016 annual result came in at $2.7 million, up 6.6% from the prior year.
- Net Equity Issued and Repurchased held at $550000.0 in Q4 2014, from $550000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $550000.0 in Q3 2014 to a low of $550000.0 in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 550,000.00 |
| Dec 31, 2014 | 550,000.00 |
| Sep 30, 2014 | 550,000.00 |
| Sep 30, 2014 | 550,000.00 |